Welcome Healthcare professionals

Select your patient’s Pfizer treatment to
download the enrolment form

Download Enrolment Form

Send the completed form to
[email protected]om

Direct your patients to
visit abrilada.ca for more
information

Download Enrolment Form

Send the completed form to
[email protected]om

Direct your patients to visit inflectra.ca for more information

Download RA Enrolment Form

Download GPA/MPA Enrolment Form

Send the completed form to
[email protected]om

Direct your patients to visit ruxience.ca for more information

Download Enrolment Form

Send the completed form to
[email protected]om

Direct your patients to visit xeljanz.ca for more information

Services for you and your patients

Registering in the PfizerFlex Patient Support Program gives your patients access to a PfizerFlex Care Coach (nurse coordinator) and all our associated services to help them get the most out of their treatment plan.
Comprehensive support to help your patients manage their treatment, including:

Enrolment
designed to be
simple and rapid

Reimbursement
navigation and
financial assistance

A dedicated
program
coordinator

Drug coordination
and infusion/
injection services

Education and
adherence support

^PrABRILADA^® (adalimumab)

ABRILADA is indicated for reducing the signs and symptoms, inducing major clinical response and clinical remission, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. ABRILADA can be used alone or in combination with methotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs).
When used as first-line treatment in recently diagnosed patients who have not been previously treated with MTX, ABRILADA should be given in combination with MTX. ABRILADA can be given asmonotherapy in case of intolerance to MTX or when treatment with MTX is contraindicated.

For more information:

Please consult the Product Monograph at http://pfizer.ca/pm/en/ABRILADA.pdf for important information relating to other indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.

^PrINFLECTRA^®(infliximab)

INFLECTRA is indicated for use in combination with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage and improvement in physical function in adult patients with moderately to severely active rheumatoid arthritis.

For more information:

.Please consult the Product Monograph at http://pfizer.ca/pm/en/INFLECTRA.pdf for important information relating to other indications, contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.

^PrRUXIENCE^® (rituximab)

RUXIENCE in combination with methotrexate is indicated in adult patients to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumour necrosis factor (TNF) inhibitor therapies. Rituximab in combination with methotrexate has been shown to reduce the rate of progression of joint damage as measured by x-ray.
RUXIENCE in combination with glucocorticoids is indicated for the induction of remission in adult patients with severely active Granulomatosis with Polyangiitis (GPA, also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA). Consideration should be given to current treatment guidelines for vasculitis.

For more information:

Please consult the Product Monograph at http://pfizer.ca/pm/en/RUXIENCE.pdf for important information relating to contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.

^PrXELJANZ^® XR / ^PrXELJANZ^® (tofacitinib)

XELJANZ/XELJANZ XR, in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of rheumatoid arthritis (RA) in adult patients with moderately to severely active RA who have had an inadequate response to MTX and to one or more disease-modifying anti-rheumatic drugs (DMARDs). In cases of intolerance to MTX and other DMARDs, physicians may consider the use of XELJANZ/XELJANZ XR (tofacitinib) as monotherapy.

For more information:

Please consult the Product Monograph at http://pfizer.ca/pm/en/XELJANZ.pdf and an Important Safety Information Advisory available at https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2021/75315a-eng.php for important information relating to other indications, contraindications, warnings, precautions, adverse reactions,interactions, dosing, and conditions of clinical use. The Product Monograph is also available by calling 1-800-463-6001.